CSL (ASX:CSL) Down 44% YTD at Decade Lows: Buying Opportunity or Falling Knife?

CSL Hits Decade Lows: Buy the Dip or Wait?

CSL (ASX:CSL) shares slipped another 2% today, extending yesterday’s brutal sell-off that pushed the stock to its lowest level since 2017. The biotech heavyweight is now down around 44% for the year, a fall few investors would have thought possible for what was long considered one of the safest blue chips on the ASX. The damage was done after interim CEO Gordon Naylor used his first 90 days in the job to slash FY26 guidance and flag US$5 billion in fresh writedowns. The real question for investors today is simple: Is this a generational buying opportunity or a falling knife not worth catching?

What are the Best ASX Stocks to invest in right now?

What Triggered the Crash

The headline number is the US$5 billion writedown, most of it tied to CSL’s 2022 acquisition of Swiss iron and renal-care business Vifor for US$11.7 billion. It is the third-largest impairment in ASX history. But in our view, the writedown is not what really spooked the market. The impairment is non-cash, meaning it does not drain the company’s bank account.

The bigger blow was the guidance cut. CSL admitted that revenue and profit for FY26 will come in lower than the market expected, weighed down by weaker conditions in the US, China and the Middle East. The message investors heard was simple: the turnaround is taking longer than promised, again.

The Bull Case vs. The Bear Case

The bull case is straightforward. The core plasma business (Behring) remains globally dominant and difficult to replicate, and the stock is now trading at levels last seen nearly a decade ago. Jarden, even after downgrading to neutral, still has a price target of A$191, which implies more than 90% upside from here. For long-term investors, the risk-reward looks materially better than it did just a week ago.

The bear case is just as compelling. Three major brokers downgraded within 24 hours, with Citi setting a target around A$110 and Canaccord at around A$106. Naylor is only 90 days into the job; his execution is unproven, and the search for a permanent CEO is still ongoing. With full-year results not due until 18 August, the stock could easily drift lower as patient investors wait for evidence that the recovery is real.

The Investor’s Takeaway for CSL: Buy or Wait?

We are not calling the bottom. But in our view, the risk-reward has materially improved for patient investors and meaningfully worsened for anyone chasing momentum.

For long-term buyers with a 3 to 5 year horizon, dollar-cost averaging into the weakness is more sensible than waiting for a clean bottom that may never form. For existing holders, selling at decade lows simply crystallises the loss when the core plasma franchise still justifies most of today’s A$47 billion market cap. For new buyers wanting confirmation, the 18 August results are the catalyst worth waiting for. Until then, in our view, patience pays better than panic.